medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2022-16-6-92-99medsovet-6817Research ArticleГАСТРОЭНТЕРОЛОГИЯGASTROENTEROLOGYФосфолипиды при неалкогольной жировой болезни печениPhospholipids in non-alcoholic fatty liver diseasehttps://orcid.org/0000-0002-2164-3537СкворцовВ. В.SkvortsovV. V.

д.м.н., профессор кафедры внутренних болезней,

400131, Волгоград, пл. Павших борцов, д. 1

Dr. Sci. (Med.), Professor of the Department of Internal Diseases, 

1, Pavshikh Bortsov Square, Volgograd, 400131

vskvortsov1@ya.ruhttps://orcid.org/0000-0001-8815-2794ЛуньковМ. В.LunkovM. V.

клинический ординатор,

197341, Санкт-Петербург, ул. Аккуратова, д. 2

Clinical Resident, 

2, Akkuratov St., St Petersburg, 197341

lunkovmax93@mail.ruhttps://orcid.org/0000-0003-1296-9073ТинаеваР. Ш.TinaevaR. Sh.

студентка,

400131, Волгоград, пл. Павших борцов, д. 1

Student,

1, Pavshikh Bortsov Square, Volgograd, 400131

tinaeva2001@yandex.ruhttps://orcid.org/0000-0002-8309-7244СкворцоваЕ. М.SkvortsovaE. M.

ассистент кафедры теоретической биохимии с курсом клинической биохимии, 

400131, Волгоград, пл. Павших борцов, д. 1

Assistant of the Department of Theoretical Biochemistry with the course of Clinical Biochemistry,

1, Pavshikh Bortsov Square, Volgograd, 400131

kat.sqo@gmail.comВолгоградский государственный медицинский университетРоссияVolgograd State Medical UniversityRussian FederationНациональный медицинский исследовательский центр имени В.А. АлмазоваРоссияAlmazov National Medical Research CentreRussian Federation202224042022069299Copyright © Скворцов В.В., Луньков М.В., Тинаева Р.Ш., Скворцова Е.М., 20222022Скворцов В.В., Луньков М.В., Тинаева Р.Ш., Скворцова Е.М.Skvortsov V.V., Lunkov M.V., Tinaeva R.S., Skvortsova E.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6817

Неалкогольная жировая болезнь печени (НАЖБП) – это патология, которая обычно имеет метаболическую причину и не вызвана чрезмерным употреблением алкоголя. НАЖБП является наиболее частым хроническим заболеванием печени во  всем мире и сопровождается высокими финансовыми затратами для пациента и системы здравоохранения. НАЖБП обычно считается «доброкачественным заболеванием» с низким уровнем прогрессирования до фиброза, цирроза и гепатоцеллюлярной карциномы (ГЦК). Тем не менее из-за большого числа заболевших распространенность цирроза печени постепенно увеличивалась, и НАЖБП фактически стала третьей причиной трансплантации печени в мире. Более того, даже если частота ГЦК у пациентов с НАЖБП ниже, чем у пациентов с циррозом в исходе вирусного гепатита С или B, абсолютное число ГЦК, связанной с неалкогольным стеатогепатитом (НАСГ), выше из-за более высокого числа пациентов с НАЖБП. Вполне вероятно, что значимость этого заболевания будет продолжать расти в будущем, когда новые методы лечения и программы профилактики гепатита С и В уменьшат размер вирусных инфекций печени. Многие аспекты НАЖБП еще предстоит исследовать. Необходимо изучить механизмы, лежащие в основе возникновения и развития заболевания, особенности клиники и диагностики, а также тактики ведения и лечения пациентов. Больным важно иметь полное представление о НАЖБП, чтобы они могли принимать активное участие в лечении заболевания. 

Non-alcoholic fatty liver disease, or NAFLD – is a pathology that usually has a metabolic cause and is not caused by excessive alcohol consumption. NAFLD is the most frequent chronic liver disease worldwide and is accompanied by a high financial burden for the patient and the healthcare system. NAFLD is generally considered a “benign disease” with low progression to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Nevertheless, due to the large number of affected patients, the prevalence of cirrhosis of the liver has gradually increased, and in fact it represents the third cause of liver transplantation in the world. Moreover, even if the frequency of HCC in patients with NAFLD is lower than in patients with HCV/HBV cirrhosis, the absolute number of HCC associated with NASH is higher due to the higher number of patients with NAFLD. It is likely that the importance of this disease will continue to grow in the future, when new treatments and prevention programs for hepatitis C and B reduce the size of viral liver infections. Many aspects of the disease have yet to be solved. It is very important to understand the mechanisms underlying the occurrence and development of NAFLD, the features of the clinic and diagnosis, as well as the tactics of management and treatment of patients with non-alcoholic fatty liver disease. It is important for patients to get a complete understanding of NAFLD so that they can play an active role in the treatment of their disease. 

неалкогольная жировая болезнь печениметаболический синдромфосфолипидыстеатозфиброзnon-alcoholic fatty liver diseasemetabolic syndromephospholipidssteatosisfibrosistreatmentclinical caseReferencesAllen A.M., Therneau T.M., Larson J.J., Coward A., Somers V.K., Kamath P.S. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018;67(5):1726– 1736. https://doi.org/10.1002/hep.29546.Allen A.M., Therneau T.M., Larson J.J., Coward A., Somers V.K., Kamath P.S. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018;67(5):1726– 1736. https://doi.org/10.1002/hep.29546.Goldner D., Lavine J.E. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology. 2020;158(7):1967–1983. https://doi.org/10.1053/j.gastro.2020.01.048.Goldner D., Lavine J.E. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology. 2020;158(7):1967–1983. https://doi.org/10.1053/j.gastro.2020.01.048.Temple J.L., Cordero P., Li J., Nguyen V., Oben J.A. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 2016;17(6):947. https://doi.org/10.3390/ijms17060947.Temple J.L., Cordero P., Li J., Nguyen V., Oben J.A. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 2016;17(6):947. https://doi.org/10.3390/ijms17060947.Lonardo A., Bellentani S., Argo C.K., Ballestri S., Byrne C.D., Caldwell S.H. et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006. https://doi.org/10.1016/j.dld.2015.08.004.Lonardo A., Bellentani S., Argo C.K., Ballestri S., Byrne C.D., Caldwell S.H. et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006. https://doi.org/10.1016/j.dld.2015.08.004.Lonardo A., Nascimbeni F., Ballestri S., Fairweather D., Win S., Than T.A. et al. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019;70(4):1457–1469. https://doi.org/10.1002/hep.30626.Lonardo A., Nascimbeni F., Ballestri S., Fairweather D., Win S., Than T.A. et al. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019;70(4):1457–1469. https://doi.org/10.1002/hep.30626.Vandel J., Dubois-Chevalier J., Gheeraert C., Derudas B., Raverdy V., Thuillier D. et al. Hepatic molecular signatures highlight the sexual dimorphism of Non-Alcoholic Steatohepatitis (NASH). Hepatology. 2021;73(3):920–936. https://doi.org/10.1002/hep.31312.Vandel J., Dubois-Chevalier J., Gheeraert C., Derudas B., Raverdy V., Thuillier D. et al. Hepatic molecular signatures highlight the sexual dimorphism of Non-Alcoholic Steatohepatitis (NASH). Hepatology. 2021;73(3):920–936. https://doi.org/10.1002/hep.31312.Rich N.E., Oji S., Mufti A.R., Browning J.D., Parikh N.D., Odewole M. et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(2):198– 210.e2. https://doi.org/10.1016/j.cgh.2017.09.041.Rich N.E., Oji S., Mufti A.R., Browning J.D., Parikh N.D., Odewole M. et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(2):198– 210.e2. https://doi.org/10.1016/j.cgh.2017.09.041.Martínez L.A., Larrieta E., Kershenobich D., Torre A. The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population. Ann Hepatol. 2017;16(6):909–915. https://doi.org/10.5604/01.3001.0010.5282.Martínez L.A., Larrieta E., Kershenobich D., Torre A. The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population. Ann Hepatol. 2017;16(6):909–915. https://doi.org/10.5604/01.3001.0010.5282.Sookoian S., Pirola C.J., Valenti L., Davidson N.O. Genetic pathways in nonalcoholic fatty liver disease: Insights from systems biology. Hepatology. 2020;72(1):330–346. https://doi.org/10.1002/hep.31229.Sookoian S., Pirola C.J., Valenti L., Davidson N.O. Genetic pathways in nonalcoholic fatty liver disease: Insights from systems biology. Hepatology. 2020;72(1):330–346. https://doi.org/10.1002/hep.31229.Berná G., Romero-Gomez M. The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management. Liver Int. 2020;40(Suppl 1):102–108. https://doi.org/10.1111/liv.14360.Berná G., Romero-Gomez M. The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management. Liver Int. 2020;40(Suppl 1):102–108. https://doi.org/10.1111/liv.14360.Leung C., Rivera L., Furness J.B., Angus P.W. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–425. https://doi.org/10.1038/nrgastro.2016.85.Leung C., Rivera L., Furness J.B., Angus P.W. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–425. https://doi.org/10.1038/nrgastro.2016.85.Schwenger K.Jp., Clermont-Dejean N., Allard J.P. The role of the gut microbiome in chronic liver disease: The clinical evidence revised. JHEP Reports. 2019;1(3):214–226. https://doi.org/10.1016/j.jhepr.2019.04.004.Schwenger K.Jp., Clermont-Dejean N., Allard J.P. The role of the gut microbiome in chronic liver disease: The clinical evidence revised. JHEP Reports. 2019;1(3):214–226. https://doi.org/10.1016/j.jhepr.2019.04.004.Boursier J., Mueller O., Barret M., Machado M., Fizanne L., Araujo-Perez F. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–775. https://doi.org/10.1002/hep.28356.Boursier J., Mueller O., Barret M., Machado M., Fizanne L., Araujo-Perez F. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–775. https://doi.org/10.1002/hep.28356.Luther J., Garber J.J., Khalili H., Dave M., Bale S.S., Jindal R. et al. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. Cell Mol Gastroenterol Hepatol. 2015;1(2):222–232. https://doi.org/10.1016/j.jcmgh.2015.01.001.Luther J., Garber J.J., Khalili H., Dave M., Bale S.S., Jindal R. et al. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. Cell Mol Gastroenterol Hepatol. 2015;1(2):222–232. https://doi.org/10.1016/j.jcmgh.2015.01.001.Kolodziejczyk A.A., Zheng D., Shibolet O., Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11(2):e9302. https://doi.org/10.15252/emmm.201809302.Kolodziejczyk A.A., Zheng D., Shibolet O., Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11(2):e9302. https://doi.org/10.15252/emmm.201809302.Mazzotti A., Caletti M.T., Sasdelli A.S., Brodosi L., Marchesini G. Pathophysiology of nonalcoholic fatty liver disease: lifestyle-gut-gene interaction. Dig Dis (Basel, Switzerland). 2016;34 Suppl 1:3–10. https://doi.org/10.1159/000447275.Mazzotti A., Caletti M.T., Sasdelli A.S., Brodosi L., Marchesini G. Pathophysiology of nonalcoholic fatty liver disease: lifestyle-gut-gene interaction. Dig Dis (Basel, Switzerland). 2016;34 Suppl 1:3–10. https://doi.org/10.1159/000447275.Malhotra P., Gill R.K., Saksena S., Alrefai W.A. Disturbances in cholesterol homeostasis and non-alcoholic fatty liver diseases. Front Med (Lausanne). 2020;7:467. https://doi.org/10.3389/fmed.2020.00467.Malhotra P., Gill R.K., Saksena S., Alrefai W.A. Disturbances in cholesterol homeostasis and non-alcoholic fatty liver diseases. Front Med (Lausanne). 2020;7:467. https://doi.org/10.3389/fmed.2020.00467.Polyzos S.A., Kang E.S., Boutari C., Rhee E.-J., Mantzoros C.S. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism. 2020;111S:154203. https://doi.org/10.1016/j.metabol.2020.154203.Polyzos S.A., Kang E.S., Boutari C., Rhee E.-J., Mantzoros C.S. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism. 2020;111S:154203. https://doi.org/10.1016/j.metabol.2020.154203.Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., Ortiz-Lopez C. et al. LongTerm Pioglitazone Treatment for Patients with Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. Ann Intern Med. 2016;165(5):305–315. https://doi.org/10.7326/m15-1774.Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., Ortiz-Lopez C. et al. LongTerm Pioglitazone Treatment for Patients with Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. Ann Intern Med. 2016;165(5):305–315. https://doi.org/10.7326/m15-1774.AlKhater S.A. Paediatric non-alcoholic fatty liver disease: an overview. Obesity Reviews. 2015;16(5):393–405. https://doi.org/10.1111/obr.12271.AlKhater S.A. Paediatric non-alcoholic fatty liver disease: an overview. Obesity Reviews. 2015;16(5):393–405. https://doi.org/10.1111/obr.12271.Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. https://doi.org/10.1002/hep.29367.Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. https://doi.org/10.1002/hep.29367.Friedman S.L., Neuschwander-Tetri B.A., Rinella M., Sanyal A.J. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24(7):908–922. https://doi.org/10.1038/s41591-018-0104-9.Friedman S.L., Neuschwander-Tetri B.A., Rinella M., Sanyal A.J. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24(7):908–922. https://doi.org/10.1038/s41591-018-0104-9.Smart N.A., King N., McFarlane J.R., Graham P.L., Dieberg G. Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: A systematic review and meta-analysis. Br J Sports Med. 2018;52(13):834–843. https://doi.org/10.1136/bjsports-2016-096197.Smart N.A., King N., McFarlane J.R., Graham P.L., Dieberg G. Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: A systematic review and meta-analysis. Br J Sports Med. 2018;52(13):834–843. https://doi.org/10.1136/bjsports-2016-096197.Gundermann K.-J., Gundermann S., Drozdzik M., Prasad V.G.M. Essential phospholipids in fatty liver: a scientific update. Clin Exp Gastroenterol. 2016;9:105–117. https://doi.org/10.2147/ceg.s96362.Gundermann K.-J., Gundermann S., Drozdzik M., Prasad V.G.M. Essential phospholipids in fatty liver: a scientific update. Clin Exp Gastroenterol. 2016;9:105–117. https://doi.org/10.2147/ceg.s96362.Shiha G., Ibrahim A., Helmy A., Sarin S.K., Omata M., Kumar A. et al. AsianPacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11(1):1–30. https://doi.org/10.1007/s12072-016-9760-3.Shiha G., Ibrahim A., Helmy A., Sarin S.K., Omata M., Kumar A. et al. AsianPacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11(1):1–30. https://doi.org/10.1007/s12072-016-9760-3.Koutoukidis D.A., Astbury N.M., Tudor K.E., Morris E., Henry J.A., Noreik M. et al. Association of Weight Loss Interventions with Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Metaanalysis. JAMA Intern Med. 2019;179(9):1262–1271. https://doi.org/10.1001/jamainternmed.2019.2248.Koutoukidis D.A., Astbury N.M., Tudor K.E., Morris E., Henry J.A., Noreik M. et al. Association of Weight Loss Interventions with Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Metaanalysis. JAMA Intern Med. 2019;179(9):1262–1271. https://doi.org/10.1001/jamainternmed.2019.2248.Cheng S., Ge J., Zhao C., Le S., Yang Y., Ke D. et al. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fattyliver-disease: A randomized controlled trial. Sci Rep. 2017;7(1):15952. https://doi.org/10.1038/s41598-017-16159-x.Cheng S., Ge J., Zhao C., Le S., Yang Y., Ke D. et al. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fattyliver-disease: A randomized controlled trial. Sci Rep. 2017;7(1):15952. https://doi.org/10.1038/s41598-017-16159-x.European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. https://doi.org/10.1016/j.jhep.2016.11.002.European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. https://doi.org/10.1016/j.jhep.2016.11.002.Mantovani A., Byrne C.D., Scorletti E., Mantzoros C.S., Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab. 2020;46(6):427–441. https://doi.org/10.1016/j.diabet.2019.12.007.Mantovani A., Byrne C.D., Scorletti E., Mantzoros C.S., Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab. 2020;46(6):427–441. https://doi.org/10.1016/j.diabet.2019.12.007.BasuRay S., Smagris E., Cohen J.C., Hobbs H.H. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology. 2017;66(4):1111–1124. https://doi.org/10.1002/hep.29273.BasuRay S., Smagris E., Cohen J.C., Hobbs H.H. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology. 2017;66(4):1111–1124. https://doi.org/10.1002/hep.29273.

The authors declare that there are no conflicts of interest present.